Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells

Cellular Oncology

Volumn 27, Issue 1, 2005, Pages 43-49

  Greijer, A E ^a   De Jong, M C ^a   Scheffer, G L ^a   Shvarts, A ^b   Van Diest, P J ^b   Van Der Wall, E ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acidification; Doxorubicin; Hypoxia; Mitoxantrone; Multiple drugs resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ACIDIFICATION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CELL ASSAY; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG TRANSPORT; DRUG UPTAKE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIC CELL; IC 50; LUNG NON SMALL CELL CANCER; PH MEASUREMENT; PRIORITY JOURNAL;

ANOXIA; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOLYSIS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOBLOTTING; INHIBITORY CONCENTRATION 50; MITOXANTRONE; P-GLYCOPROTEIN;

EID: 15244344783     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. J.D. Allen, A. van Loevezijn, J.M. Lakhai, M. van der Valk, V.O. van Tellingen, G. Reid, J.H. Schellens, G.J. Koomen and A.H. Schinkel, Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C, Mol. Cancer Ther. 1 (2002), 417.
2. R. Bos, P. van Der Groep, A.E. Greijer, A. Shvarts, S. Meijer, H.M. Pinedo, G.L. Semenza, P.J. van Diest and E. van der Wall, Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma, Cancer 97 (2003), 1573.
3. J.M. Brown, The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture, Cancer Res. 59 (1999), 5863.
4. K.M. Comerford, T.J. Wallace, J. Karhausen, N.A. Louis, M.C. Montalto and S.P. Colgan, Hypoxia-inducible factor-1-dependent regulation of the Multidrug Resistance (MDR1) gene, Cancer Res. 62 (2002), 3387.
5. W.S. Dalton, Mechanisms of drug resistance in breast cancer, Semin. Oncol. 17 (1990), 37.
6. M.C. de Jong, J.W. Slootstra, G.L. Scheffer, A.B. Schroeijers, W.C. Puijk, R. Dinkelberg, M. Kool, H.J. Broxterman, R.H. Meloen and R.J. Scheper, Peptide transport by the multidrug resistance protein MRP1, Cancer Res. 61 (2001), 2552.
7. L.A. Doyle and D.D. Ross, Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2), Oncogene 22 (2003), 7340.
8. S.M. Evans and C.J. Koch, Prognostic significance of tumor oxygenation in humans, Cancer Lett. 195 (2003), 1.
9. F. Gieseler, A. Glasmacher, D. Kampfe, H. Wandt, V. Nuessler, S. Valsamas, J. Kunze and K. Wilms, Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines, Leukemia 10 (1996), 1177.
10. T.G. Graeber, C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe and A.J. Giaccia, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours, Nature 379 (1996), 88.
11. M. Hockel and P. Vaupel, Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects, J. Natl. Cancer Inst. 93 (2001), 266.
12. 2 homeostasis by hypoxia-inducible factor 1 alpha, Genes Dev. 12 (1998), 149.
13. E. Jahde, K.H. Glusenkamp and M.F. Rajewsky, Protection of cultured malignant cells from mitoxantrone cytotoxicity by low extracellular pH: a possible mechanism for chemoresistance in vivo, Eur. J. Cancer 26 (1990), 101.
14. S.V. Kozin, P. Shkarin and L.E. Gerweck, The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics, Cancer Res. 61 (2001), 4740.
15. C.M. Kuiper, H.J. Broxterman, F. Baas, G.J. Schuurhuis, H.J. Haisma, G.L. Scheffer, J. Lankelma and H.M. Pinedo, Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin, J. Cell Pharmacol. 1 (1990), 35.
16. B.P. Mahoney, N. Raghunand, B. Baggett and R.J. Gillies, Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro, Biochem. Pharmacol. 66 (2003), 1207.
17. M. Maliepaard, G.L. Scheffer, I.F. Faneyte, M.A. van Gastelen, A.C. Pijnenborg, A.H. Schinkel, M.J. van De Vijver, R.J. Scheper and J.H. Schellens. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues, Cancer Res. 61 (2001), 3458.
18. N. Raghunand and R.J. Gillies, pH and drug resistance in tumors, Drug Resist. Updat. 3 (2000), 39.
19. K.J. Reszka and C.F. Chignell, Acid-catalyzed oxidation of the anticancer agent mitoxantrone by nitrite ions, Mol. Pharmacol. 50 (1996), 1612.
20. D.D. Ross, W. Yang, L.V. Abruzzo, W.S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S.P. Cole and L.A. Doyle, Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines, J. Natl. Cancer Inst. 91 (1999), 429.
21. G.L. Scheffer, M. Kool, M. Heijn, M. de Haas, A.C. Pijnenborg, J. Wijnholds, A. van Helvoort, M.C. de Jong, J.H. Hooijberg, C.A. Mol, M. van der Linden, J.M. de Vree, P. der van Valk, R.P. Elferink, P. Borst and R.J. Scheper, Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies, Cancer Res. 60 (2000), 5269.
22. R.J. Scheper, J.W. Bulte, J.G. Brakkee, J.J. Quak, S.E. van der Schoot, A.J. Balm, C.J. Meijer, H.J. Broxterman, C.M. Kuiper, J. Lankelma and H.M. Pinedo, Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance, Int. J. Cancer 42 (1988), 389.
23. C.W. Taylor, W.S. Dalton, P.R. Parrish, M.C. Gleason, W.T. Bellamy, F.H. Thompson, D.J. Roe and J.M. Trent, Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line, Br. J. Cancer 63 (1991), 923.
24. B.A. Teicher, Hypoxia and drug resistance, Cancer Metastasis Rev. 13 (1994), 139.
25. G.L. Wang and G.L. Semenza, Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia, J. Biol. Chem. 268 (1993), 21513.
26. O. Warburg, F. Wind and E. Negalein, The metabolism of tumours in the body, J. Physiol. 8 (1927), 519.
27. M. Wartenberg, F.C. Ling, M. Muschen, F. Klein, H. Acker, M. Gassmann, K. Petrat, V. Putz, J. Hescheler and H. Sauer, Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species, FASEB J. 17 (2003), 503.